Vijith Shetty’s Post

🔍 Breast Cancer Treatment Sequence Insights from ESMO 2024 Dr Guilherme Nader Marta (Dana Farber) shares EVERGREEN study results, showing a modest progression-free survival benefit with everolimus post-CDK4/6 inhibitors in ER+/HER2- breast cancer, especially in patients with specific genetic profiles. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #BreastCancer #Oncology #Everolimus #CancerResearch

Discover best practices to investigate novel blood cancer therapies with hematology experts Christopher Morley and Sari Heitner Enschede, MD. This insightful white paper explores how biotech companies can address the challenges around investigational agents for hematologic cancers, while considering patient diversity. https://bit.ly/3Aqv5Yw #hematology #oncology #diversity

Eric S. Winer, MD, Clinical Director of Adult Leukemia at Dana-Farber Cancer Institute, and an Assistant Professor of Medicine at Harvard Medical School, highlights the progress of TakeAim Leukemia study. He notes, "It's been terrific to see the results of emavusertib (CA-4948); what’s nice about emavusertib is it seems to work well in patients with FLT3 mutations, but also in those who have previously received FLT3 inhibitors." #CRIS #oncology #hematology #drugdevelopment #emavusertib Emavusertib Progresses to Phase 2 Study in AML and MDS (onclive.com)

Discover best practices to investigate novel blood cancer therapies with hematology experts Christopher Morley and Sari Heitner Enschede, MD. This insightful white paper explores how biotech companies can address the challenges around investigational agents for hematologic cancers, while considering patient diversity. https://bit.ly/3UrmUm8 #hematology #oncology #diversity

Biomarkers, including circulating tumor DNA (ctDNA) and immune profiling, along with antibody-drug conjugates (ADCs), are enhancing the personalization of cancer treatment, contributing to the development of precision oncology. https://ow.ly/WqIa50RYYGj #Oncology #Biomarkers

Hematologic malignancies are distinct from solid tumors and we have board-certified hematologists and oncologists on staff to support trials general and biomarker-defined rare hematologic malignancies. Dedicated expertise in your fight against blood cancer. https://bit.ly/3AtGPKh #oncology #clinicaltrials #bloodcancer

Picking PI3K mutation in Breast cancer New ASCO rapid recommendation update! Capivasertib + Fulvestrant is now recommended for HR-positive, HER2-negative metastatic breast cancer, showing significant benefits in progression-free survival. Read more https://lnkd.in/dnCXpfwY Listen to podcast on https://lnkd.in/dQnwDq96 #BreastCancer #Oncology #ASCO #TargetedTherapy #Capivasertib #Fulvestrant

Today is Gastrointestinal Stromal Tumor (GIST) Awareness Day. Let's raise awareness and support those affected by this rare cancer. Early detection and research are key to fighting GIST. #GISTAwareness #CancerResearch #EarlyDetection #OneCellDiagnostics #onecelldx #oncology #precisiononcology

🌟 𝗡𝗲𝘄 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝗔𝗹𝗲𝗿𝘁: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿” 🌟   Watch the first episode of 'What’s New Doc' in prostate cancer in which Prof Bertrand Tombal and Prof Steven Joniau discuss the results of EMBARK, evaluating enzalutamide in patients with high-risk prostate cancer and a biochemical recurrence following local therapy.   👇 Watch all WND PCa videos - link in the comments! #MediMix #ProstateCancer #Oncology

Exciting developments in prostate cancer treatment! Recent findings highlight that intensification with apalutamide and ADT significantly improves PSA progression-free survival in patients with biochemically recurrent prostate cancer. This advancement underscores the potential of targeted therapies in enhancing patient outcomes. Check out the full article for detailed insights: https://lnkd.in/dB7-hZf5 #ProstateCancer #Oncology #MedicalResearch #CancerTreatment #HealthcareInnovation